Item 2.05. Costs Associated with Exit or Disposal Activities. On May 15, 2021, Teleflex Incorporated (the "Company") entered into a definitive agreement (the "Sale Agreement") to divest certain product lines within its global respiratory product portfolio to Medline Industries, Inc. ("Medline"). In connection with its entry into the Sale Agreement, the Company committed to a restructuring plan designed to separate the manufacturing operations that will be transferred to Medline from those that will remain with the Company, which plan includes related workforce reductions (the "Plan"). The Plan includes expanding the Company's existing locations to accommodate the transfer of capacity from the sites that will be transferred to Medline and replicating the manufacturing processes at the alternate existing Teleflex locations. Initial actions under the Plan are expected to commence in the second quarter of 2021, with more substantial activities scheduled to begin after completion of the initial closing of the transactions contemplated under the Sale Agreement, which is expected to occur in the third quarter of 2021. The Plan is expected to be substantially completed by the end of 2023.

The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the Plan of $24 million to $30 million, of which the Company expects $6 million to $7 million to be incurred in 2021 and the balance to be incurred in 2022 and 2023. The Company estimates that substantially all of these charges will result in cash outlays, the majority of which will be made in 2022 and 2023. Additionally, the Company expects to incur $22 million to $28 million in aggregate capital expenditures under the plan, which are expected to be incurred mostly in 2022 and 2023.

The following table provides a summary of the Company's cost estimates by major type of expense associated with the Plan:



                                                      Total estimated amount expected to be
Type of expense                                                     incurred
Restructuring charges (1)                                   $5 million to $8 million
Restructuring related charges (2)                          $19 million to $22 million
Total restructuring and restructuring related
charges                                                    $24 million to $30 million

(1) Substantially all of the charges consist of employee termination benefit costs. (2) Consist of charges that are directly related to the Plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold.

As the Plan progresses, the Company will reevaluate the estimated expenses and charges set forth above, and may revise its estimates, as appropriate, consistent with GAAP.

Item 7.01 Regulation FD Disclosure. On May 18, 2021, the Company issued a press release announcing that it has entered into a definitive agreement to divest certain product lines within its global respiratory product portfolio to Medline. A copy of the press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release , dated May 18, 202 1 104 The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TELEFLEX INCORPORATED


                                     By: /s/ Liam J. Kelly
                                     Name: Liam J. Kelly
                                     Title: Chairman, President and
                Date: May 18, 2021         Chief Executive Officer

© Edgar Online, source Glimpses